A detailed history of Shepherd Financial Partners LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Shepherd Financial Partners LLC holds 3,766 shares of SRPT stock, worth $502,158. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,766
Previous 3,766 -0.0%
Holding current value
$502,158
Previous $595,000 21.01%
% of portfolio
0.06%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

SELL
$75.71 - $119.24 $1,741 - $2,742
-23 Reduced 0.61%
3,766 $416,000
Q1 2022

May 13, 2022

SELL
$63.15 - $90.42 $320,991 - $459,604
-5,083 Reduced 57.29%
3,789 $296,000
Q4 2021

Feb 14, 2022

SELL
$77.28 - $99.42 $927 - $1,193
-12 Reduced 0.14%
8,872 $799,000
Q3 2021

Nov 15, 2021

SELL
$65.97 - $92.48 $90,708 - $127,160
-1,375 Reduced 13.4%
8,884 $821,000
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $11,031 - $13,793
-159 Reduced 1.53%
10,259 $798,000
Q1 2021

May 14, 2021

SELL
$72.25 - $168.95 $561,671 - $1.31 Million
-7,774 Reduced 42.73%
10,418 $776,000
Q4 2020

Feb 16, 2021

BUY
$125.56 - $178.74 $88,394 - $125,832
704 Added 4.03%
18,192 $3.11 Million
Q3 2020

Nov 16, 2020

BUY
$127.12 - $172.34 $1.01 Million - $1.37 Million
7,965 Added 83.64%
17,488 $2.46 Million
Q3 2019

Nov 25, 2019

SELL
$72.81 - $156.91 $6,188 - $13,337
-85 Reduced 0.88%
9,523 $717,000
Q1 2019

Apr 29, 2019

SELL
$106.67 - $151.68 $5,333 - $7,584
-50 Reduced 0.52%
9,608 $1.15 Million
Q4 2018

Feb 07, 2019

SELL
$97.32 - $148.76 $1,459 - $2,231
-15 Reduced 0.16%
9,658 $1.05 Million
Q4 2017

Feb 14, 2018

BUY
$47.64 - $56.75 $63,837 - $76,045
1,340 Added 16.08%
9,673 $539,000
Q3 2017

Nov 13, 2017

BUY
$35.73 - $47.15 $297,738 - $392,900
8,333
8,333 $427,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Shepherd Financial Partners LLC Portfolio

Follow Shepherd Financial Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shepherd Financial Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shepherd Financial Partners LLC with notifications on news.